Two experts discuss best practices for antiretroviral therapy (ART) selection for people living with HIV.

Topline results from phase III PURPOSE 1 trial (NCT04994509) demonstrate the twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, achieved 100% efficacy in preventing HIV infections in cisgender women.  

Watch three experts describe the HIV life cycle, the rationale for ART and how to manage ART resistance.

A recent study published in Science Advances highlights significant and unequal declines in life expectancy in India during the COVID-19 pandemic.

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) hosted its 2024 Global Congress in Barcelona, continuing its tradition of presenting high-quality data and fostering insightful discussions.

The World Health Organization (WHO) has introduced updated guidelines for managing chronic hepatitis B, with the goal of enhancing testing, diagnosis and treatment, revealed at the 2024 Asian Pacific Conference for the Study of Liver Disease. These guidelines expand recommendations to include teenagers and emphasize patient choice and aim to simplify treatment decisions and improve access to care, particularly in resource-limited areas, by allowing treatment initiation without extensive viral testing.

Sponsored content from GSK. Watch leading experts Jeremy Szeto and Kristen Robillard discuss their personal experience with adult immunization programs and the approaches they use in their practices to help optimize adult immunization rates.

Watch three experts discuss how to optimize antiretroviral therapy for people living with HIV through an individualized approach to care

World Tuberculosis (TB) Day is observed annually on 24 March to raise awareness about tuberculosis and to commemorate the discovery of the Mycobacterium tuberculosis bacterium (M.tb) by Dr Robert Koch in 1882. It aims to educate people about the impact of ...